At Horizons in Advanced Practice, Evangelia Nezis, NP, shares early results with oral peptides and takeaways on type 2 ...
Mark Lebwohl, MD, discusses atopic march data and systemic treatment options for pediatric atopic dermatitis. Mark Lebwohl, ...
A melanoma expert discusses gaps in dermoscopy education, cognitive bias during skin examinations, and strategies to improve ...
C, shares how journal case reports led to rapid results for a patient with an uncommon skin condition. After nearly 10 years on isotretinoin with minimal improvement, Sharon Doering, PA-C, tried a ...
Afamelanotide is effective, yet access, cost, and travel limit its use. The discussion considers adherence, the promise of oral therapies, and how dermatologists, hepatologists, and hematologists ...
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before ...
Aclaris Therapeutics announced positive phase 1b proof-of-concept results for ATI-052, an investigational bispecific antibody ...
Patients on Medicare often do everything insurers ask, including trying and failing the standard topicals, and still can’t ...
Lutikizumab (ABT-981) met its primary end point and all 8 ranked secondary end points in the phase 3 INTREPID trial ...
The FDA has accepted Lynch Regenerative Medicine’s (LRM) investigational new drug (IND) application for a phase 2b clinical ...
Oral JAK inhibitors are preferred first-line long-term therapy for severe adult AA; FDA-approved agents are favored, whereas ...
In "Transitioning From Self-Injection to HCP-Administered Psoriasis Therapy," our experts examine what to do when a patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results